3C Bio Announces Formation of Rapid Deployment Mobile Diagnostic Laboratory Company and Winning the XX: Fight the Virus Business Accelerator Competition
SAN PEDRO, CA, August 13, 2020 — 3C Bio, Inc. (“3C Bio”), an in vitro diagnostics company that builds, sells, and operates rapidly deployable mobile laboratories optimized for SARS-CoV-2 diagnostic screening for critical on-site workplace and event screening. In April, 3C Bio was selected as one of 11 winners (of 2,500 international applicants) in the XX: Fight the Virus Challenge. Enrolled in their 4-month business accelerator program 3C Bio was awarded $50,000 in pre-seed funding for their innovative mobile testing solutions, culminating in a DemoDay launch on the crowdfunding platform, Wefunder, where 3C Bio has raised another $51,000.
“We will supply semi-robotic, rapidly deployable, mobile laboratories to workplaces, schools, resorts, and institutions to rule out infection, prevent transmission and protect entire workforces and the consumers and communities they serve,” said David Therrien, Founder and Director of Strategy & Design of 3C Bio. “Our scalable approach to providing critical testing on-site infrastructure is to build custom laboratories in semi-trailers and ISO shipping containers that can test at a large daily capacity. Additionally, our sample collection methodologies enable our labs to process up to 2,400 verified RT-qPCR tests per day, with same day results. By deploying multiple units for testing at large-scale events we can make it safe to gather for the social activities that we love once again.”
In the midst of the ever-evolving pandemic, the high risk of contracting SARS-CoV-2 from asymptomatic and pre-symptomatic carriers leaves us all vulnerable to the dangers of Covid-19. Without a significant increase in testing capacity, the impact on our economy and society will continue worsen. Clinical lab testing incumbents, such as LabCorp and Quest, have a vast infrastructure for receiving samples from medical facilities and clinics. Unfortunately, this infrastructure is configured in a manner that is limited in its ability to rapidly verify and clear workplaces, institutions, recreational activities, and other settings.
“Since the earliest days of the pandemic, the choke point has been diagnostic testing. It has been a privilege to help build upon the compelling concept David has engineered and designed,” said Mark Mendel, Ph.D., Chief Executive Officer of 3C Bio. “despite public health measures taken here in the US, this deadly virus’s trajectory continues to worsen. We are at war with COVID-19, and our goal at 3C Bio is to win that war by providing a major component that will clear entire workforces, which is essential for the safe reopening of our economy.”
Until a widely deployed vaccine is available, extensive repetitive testing will be required for maintaining essential services and facilitating a full restart of the economy. 3C Bio does this by offering a broader logistical footprint that is optimized for non-healthcare settings. To ensure the safe reopening of factories, schools, events, and travel, massive-scale, on-site verified testing may be the most effective “gate-keeper” to protect public health, stabilize operations, and re-instill confidence in the participation that is essential for a healthy economy.
“With the need for millions of tests per day nationwide, the growth of asymptomatic cases, and the rising strain on healthcare resources; the accessibility of rapid, combined viral & antibody testing is critical in efforts to identify and quickly isolate infected patients to further reduce the tremendous burden on existing healthcare infrastructure,” said Jason Goldman, MD, MPH, an infectious disease specialist in Seattle, WA and COVID-19 expert. “The 3C Bio mobile diagnostic solution is incredibly valuable as it simultaneously diagnoses and stages a SARS-CoV-2 infection with a high degree of accuracy using a combination of RT-qPCR testing for the virus and IgM/IgG serology testing for antibodies to the virus.”
About 3C Bio
3C Bio, Inc., located in Los Angeles, CA, builds, sells, and operates rapidly deployable mobile laboratories optimized for SARS-CoV-2 (COVID-19) diagnostic screening using FDA EUA approved methods. Labs are designed for critical on-site workplace and event screening of up to 2,400 people daily, per lab, with same day results. Bypassing logistical barriers of traditional laboratory and clinical settings, 3C Bio’s mobile, high-volume, high-complexity laboratories are designed for maximum scalability. With our high-throughput automated robotic pipeline, the laboratories are configured for Real-time qPCR testing, and are designed with the flexibility to be outfitted with wide-ranging laboratory diagnostic systems to quickly adapt to changing public health pandemic needs. For more information, please visit www.3cbio.com
About XX and Wefunder
XX is an early-stage startup accelerator established by Wefunder with the intention to create 20,000 new startups within a decade, and also provides more experienced founders with the opportunity to invest in startups a few years behind them.Wefunder, a Public Benefit Corporation founded in 2011, is the nation’s leading crowdfunding investment platform, with
a mission to help keep the American dream alive. They have raised almost $130 million for hundreds of companies that have gone on to raise over $2 billion in venture capital.
For more information, please visit www.wefunder.com/3cbio